Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inspire Medical Systems (INSP) EBITDA (2017 - 2025)

Inspire Medical Systems' EBITDA history spans 9 years, with the latest figure at $135.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 299.05% year-over-year to $135.9 million; the TTM value through Dec 2025 reached $145.4 million, up 172.98%, while the annual FY2025 figure was $145.4 million, 172.98% up from the prior year.
  • EBITDA for Q4 2025 was $135.9 million at Inspire Medical Systems, up from $10.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $135.9 million in Q4 2025 and bottomed at -$17.0 million in Q3 2022.
  • The 5-year median for EBITDA is -$6.0 million (2023), against an average of $4.6 million.
  • The largest annual shift saw EBITDA surged 352.85% in 2023 before it plummeted 135.83% in 2025.
  • A 5-year view of EBITDA shows it stood at -$2.4 million in 2021, then skyrocketed by 240.62% to $3.4 million in 2022, then skyrocketed by 352.85% to $15.5 million in 2023, then soared by 119.47% to $34.1 million in 2024, then surged by 299.05% to $135.9 million in 2025.
  • Per Business Quant, the three most recent readings for INSP's EBITDA are $135.9 million (Q4 2025), $10.2 million (Q3 2025), and -$3.4 million (Q2 2025).